<DOC>
	<DOCNO>NCT00666016</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability short term effect liver enzymes TRO19622 500 mg one month patient Non-Alcoholic Steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>Exploratory Study Assess Short Term Effect Liver Enzymes Safety TRO19622 Patients With Non-Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult subject older 18 year . Persistent ALT elevation ( &gt; 2 time ULN local laboratory investigate site ) 6 month prior entry study . No one ALT value within normal range past year . Patients must ALT measurement least every 6 month within year inclusion . Histologically confirm diagnosis steatohepatitis biopsy within 2 year prior entry protocol . Compensated liver disease follow hematologic , biochemical , serological criterion entry protocol : Hemoglobin &gt; 11 gm/dL female &gt; 12 gm/dL male White blood cell ( WBC ) &gt; 2.5 K/UL Neutrophil count &gt; 1.5 K/UL Platelets &gt; 100 K/UL Total bilirubin &lt; 35 Âµmol/L ) Albumin &gt; 36 g/L TP &gt; 80 % . Serum creatinine within normal limit No cause chronic liver disease ( autoimmune , primary biliary cirrhosis , HBV , Wilson , alpha1antitrypsin deficit , hemochromatosis etc\dots ) If applicable , stable diabetes , define HbA1c &lt; 9 % fast glycemia &lt; 10 mmol/L , change medication previous 6 month , new symptom associate diabetes previous 3 month . If applicable stable metabolic condition ( diagnosis make least 6 month inclusion ) , without major weight laboratory test change . Negative pregnancy test post menopausal . Have electrocardiogram ( ECG ) without clinically significant abnormality . Subjects must willing give write informed consent . Evidence another form liver disease . History excess alcohol ingestion : daily alcohol consumption &gt; 30 g/day ( 3 drink per day ) males &gt; 20 g/day ( 2 drinks/day ) female . Unstable metabolic condition : Weight change &gt; +/ 10 % previous year , diabetes poor glycemic control ( HbA1c &gt; 9 % ) , introduction antidiabetic antiobesity drug past 6 month prior screen . History gastrointestinal bypass surgery ingestion drug know produce hepatic steatosis include corticosteroid , highdose estrogen , methotrexate , tetracycline amiodarone previous 6 month . Significant systemic major illness liver disease , include congestive heart failure , coronary artery disease , cerebrovascular disease , pulmonary disease , renal failure , organ transplantation , serious psychiatric disease , malignancy , opinion investigator would preclude treatment TRO19622 and/or adequate follow . HIV infection . Active substance abuse , inhale injection drug within previous year . Pregnancy inability practice adequate contraception woman childbearing potential . Active malignancy except cutaneous basocellular carcinoma . Any condition , opinion investigator would impede competence compliance possibly hinder completion study . Body mass index ( BMI ) &gt; 40 kg/m2 ( obesity Grade III ) . Type 1 diabetes Insulintreated type 2 diabetes . Hemostasis disorder current treatment anticoagulant . History , current cardiac dysrhythmias / history cardiovascular disease , include myocardial infarction , except patient well control hypertension . Participation investigational drug therapy study within previous 3 month . Be possibly dependent Investigator Sponsor ( eg , include , limited , affiliated employee ) . Medications could interfere TRO19622 absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>non alcoholic steatohepatitis nash hepatoprotective hepatoprotection ALT AST new drug candidate interventional study TRO19622 Trophos cholest-4-en-3-one oxime</keyword>
</DOC>